Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018		Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 8,034		$ 7,600
Marketable equity securities	428		760
Prepaid expenses and other current assets	180		168
Total current assets	8,642		8,528
NONCURRENT ASSETS
Intangible assets, net		[1]	746
Machinery and equipment, net	614		822
Deposits and other noncurrent assets	262		120
TOTAL ASSETS	9,518		10,216
CURRENT LIABILITIES
Amount due to BioTime and affiliates	2,101		2,099
Accounts payable	166		175
Accrued expenses and other current liabilities	2,109		1,042
Loan payable, current	800		800
Capital lease liability, current	385		338
Total current liabilities	5,561		4,454
NONCURRENT LIABILITIES
Loan payable, net of deferred financing costs, noncurrent	347		1,070
Capital lease liability, noncurrent	187		289
TOTAL LIABILITIES	6,095		5,813
Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding
Common stock, no par value, 85,000 shares authorized; 40,664 and 31,452 shares issued and outstanding at December 31, 2018 and 2017, respectively	74,742		59,968
Accumulated other comprehensive loss			(888)
Accumulated deficit	(71,319)		(54,677)
Total stockholders' equity	3,423		4,403
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 9,518		$ 10,216

[1] As part of OncoCyte's impairment assessment of certain intangible assets, OncoCyte determined that those assets were impaired as of June 30, 2018 and, accordingly, OncoCyte recorded a noncash charge of $625,000 representing the net book value of those assets as of that date, and included that charge in research and development expenses for the year ended December 31, 2018. The impairment was primarily due to OncoCyte's decision to discontinue any further utilization of the underlying patents, patent applications and licenses since those assets are for therapeutic use and not for diagnostic use, as OncoCyte continues to devote all of its research and development resources and commercialization efforts to cancer diagnostic tests. Research and development expenses for the year ended December 31, 2018 include $121,000 in amortization expense related to those intangible assets recorded prior to the impairment charge. For the year ended December 31, 2017, research and development expenses include $242,000 of amortization of intangible assets.